A bst ract Mu ltipl e niyeloma , which primarily aifeets the elderly, is rare in the head and ne ck. We report the ease oja 7J-yearold man who came to IIS with hoarseness , dysphagia, int ermittent aspiration, and cervieal lymphadenopathy. Our work-up included laboratory tests, radiographic examinations, ana lysi s ofbone tnarrow aspiration, and histopathologic evaluatio ns. Cervi cal lymph node biopsy confirmed a diagnosis ofmultiple myel oma . Despite treatm ent with chemotherapy and radiation, the patient died of his disease 6 months later.
Introduction
Multip le myeloma, a rare malignancy of plasma ce lls, was first described in 1950 as an abnormal prod uction of imm unog lobulins.' It acco unts for approximately l O to 15% of all hematologic malignancies, I % of all malignant neo plasms in whites and 2% in blacks, and 2% of deat hs from all rnalignancies.' :'
Multiple myeloma represents fewer than 2% of all head and neck cancers.' :' When it has been reported in the head and neck , it involved the skull base, orbit, sca lp, forehead, paranasal sinuses, mandible, palate, tong ue, larynx, and thyroid gland.l?
The etiology of multiple myelom a is unelear. Race, genetics, geography, and expo sure to radiation and occupational substances have all been implicated in its de vel- opment.'" Occupational risk factor s inelude exposure to wood, meta l, rubber, texti les, and petroleurn.' Population-based studies have shown that blacks experience both a higher incidenee of this malignancy and higher mortality from it.' Multiple myeloma is rarely seen in patients younger than 40 years; its peak incidenee occurs in the sixth and seventh decades of life.' -'
The eli nical manifestations of multiple myeloma inelude bone pain, anemia, hypercalcemia, and renal disease. Amyloidosis has also been seen.' Init ial symptoms in the head and neck may inel ude headache, confusion, irritability, diplopia, blurred vision , heari ng loss, ver tigo , hoarseness, dysphagia, and cra nial nerve defici ts.'-'
Case report
A 71-year-old black man ca me to us wit h a 3-mo nth history of progressive hoarseness and dys phagia and inter mitten t aspiration. He denied using any medications, alcohol, or tobacco. He reported that he ofte n app lied a commercially avai lable topieal analgesic cream to relieve persisten t left shoulder pai n. His medical and surgical histories were unremarkable.
Physical examination revealed that he was a welldeveloped, well-nourished man with mild hoarseness. Findings on head , eyes, and ENT examination were normal except for the fact that his tong ue deviated to the left upon protru sio n and his gag reflex was diminished on the left. Indirect laryngoscopy reve aled left vocal fold paralysis. Cervical adenopathy of the left posterior triangle was noted.
Laboratory testing revealed moderate normochromic , normocytic anemia (hemoglobin: 10.5 g/d l; mean corpuscu lar volume : 8 1.9 11m3; mean corpuscular hemoglobin : 26.9 g/dl ; and white blood ce ll count: 11 .4 x 103/111). His plate let count was norma!. Th e differential co unt revealed 85% polymor phonuelear leu kocytes, 9% lymph ocytes, ENT-Ear, Nose & Throat Joumal s April 2004 3% monoeytes, 3% bands, and 4+ rouleaux forms. Benee Jones proteinuria was absent. Sub sequent urine immunoeleetroph oresis revealed the presenee of M subclass proteinuri a.
Fin dings on fine-need le aspiration biopsy (FNA B) of the neek mass were equivocal, demonstrating only abnormai eeli s. Comp uted tomography suggested fullness at the left base of the tong ue. Magnetie resonanee imagin g (MRI) revealed the presenee of a mass in the left skull base that involved the clivus and the tempo rai bone (figure I , A). Its epicent er was loeated in the area of the ju gul ar foramen. The mass was approxim ately 5 cm wide, and its antero posterior diameter was 2.5 cm, The lesion obseured the region of the left hypoglossal ean al and abutted the left earotid artery . The mass indented the left eere bellar hemisphere poster iorly and extended laterally to the mastoid air eelis (figure I, B). The differential diagnosis suggested by these findings included meningioma , plasmaeytoma, Iymphoma, and metastatie carcinoma.
Direet laryngoseopy, esophagoseopy, and bronehoseopy were performed with the patient under genera l anesthesia. Random biopsies were taken from the nasophary nx, base of the tongue, tonsillar fossa, and pyriform sinus. The left voca l fold paralysis was noted, as _ weil. A posterior eer viea l Iymph node was exei sed and sent for froze n-seetio n analysis. Examination of the specimen reve aled sheets of atypieal plasma eelis with foei of normal Iymphoeytes (figure 2, A). Immunoperoxidase stains of the plasma eeli s for B-or T-eeli markers were negative. Kappa and lamb da preparations were inadequate for interpretation.
Bone marrow aspiration eytology revea led norm al eellularity, with myeloid , ery throid, and megakaryoe yte ee li lines present. There were areas of patehy plasmaeytosis, with inereased numb ers of plasma eelis that had abnor mal shapes and abnormal nucl ei (figure 2, B). Serum electrophoresis demonstrated a monoclo nal spike in the gamm a globulin regio n. The findings of this spike and the bone marrow plasmaeytosis strongly suggested a diagnosis of multiple myeloma. Exeept for the skull and the temp orai bone, the results of a bone sea n were negative.
The patient was started on six eye les of vineris tine, earmu stine, and eye lophos phamide on the first day of treatment. After 12 wee ks, he was plaeed on six eycles of maintenanee treatment with I mg/kg of melph alan for 10 days and 60 mg of pred nisone tapered over 5 days. He also reeei ved 4,000 eGy of radiation therapy to the neek over a 4-w eek perio d. Two months after the start of treatment, bone marrow aspiration revealed minimal ehange . Vineristine, doxorubiein, and dexamethasone were then give n over a 5-week period. However, the patient' s symptoms progressed , and he died 6 months after the initial diagnosis. PRECAUTlONS:
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WARNING
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Hemostatk: Sea/ant
Diseussion
Multiple myeloma is cha racterized by a proliferation of pla sm a cells that produ ce M proteins and an overproduction of myeloma protein and immunoglobulin .I.3 A thyroid mass may arise as an enl argin g neck mass with cervical Iymph node involvement. Thyroid masses and eervica l Iymphadenopathy can be evaluated by FNAB. FNAB is also indic ated for lesion s in the nasal cavity, oral cavity, oroph arynx, and larynx. Open biopsy may be indicated for neck and thyroid masses when FNAB is nondi agno stic. The differential diagnosis includes glomus jugul ar tu mors, cerebellopontine angle tumor, mal ign ant melan om a, esthesioneuroblastoma, undifferentiated carcinoma, Iymphoma, and plasma cell granuloma. The head and neck work-up includes a thorough exa mination , laboratory studies, and radiographi c eva luat ion. MRI is useful in detecting dissem ination of dis ease in the temporai bon e and skull base. Th e trea tme nt of choice for previo usly untreated multiple myeloma is chemothera py. Th e go ld standard for chemotherapy is melphalan and prednisone . Even so, the long-term prognosis remains dism al, although imp roved surviva l rates have been observed with this combination.P Vincristine, doxorubicin, and dex amethasone are used to treat resistant disease.
Oth er treatm ent modalities ind ude interferon , radiation therap y, and bone marrow tran splant ation. Clinical trials of interferon have dem onstrat ed that it is effect ive in decreasing the production of myeloma plasma ce lls.'" Imp roved res ponse rates have been reported when interfero n is co mbined with chemotherapy. '-' Radi ation therapy is prima rily used for pall iation since multiple myelom a is not a radiosensitive disease.' Bone nHllTOW transplantation has been useful in selected cases, but its application is limit ed . Surge ry plays a limited ro le in multipl e myeloma, although it may be useful as a means of cytoredu ction, man agin g airway obstructions, and obtaining cer vica l lymph node biopsies.'
Th e pro gnosis of multiple myelom a is poor, and mos t patient s die within 2 years of their diagnosis; 3-year surv ival is only abo ut 10%.1.2.5The average survival for patient s with sys temic multiple myeloma is less than I year. 1. 2 . 5
